Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medios AG (ILM1.DE)
Berlin, AB, DE
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -13.51% | -9.86% | -1.99% | -23.44% | -14.21% | -12.81% | +10.15% | -25.75% | -62.95% | +2,460.00% | +120.69% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+10.4% ★ Q1'26: +8.9% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+19.6% ★ Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.2% Q1'26: +1.7% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+2.0% Q1'26: +1.8% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+4.0% Q1'26: +3.7% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+2.5% Q1'26: -4.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×2.37× Q1'26: 2.65× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
133.21M
est: 160.50M (-17.0%)
|
253.64M
est: 253.00M (+0.3%)
|
327.83M
est: 327.90M (0.0%)
|
516.80M
est: 514.15M (+0.5%)
|
626.54M
est: 622.47M (+0.7%)
|
1.36B
est: 1.33B (+1.8%)
|
1.61B
est: 1.62B (-0.8%)
|
1.78B
est: 1.84B (-2.9%)
|
1.88B
est: 1.87B (+0.9%)
|
2.08B
est: 2.02B (+2.8%)
|
2.10B
2.05B – 2.14B
+3.7% YoY
|
2.17B
2.11B – 2.21B
+3.4% YoY
|
2.25B
2.22B – 2.28B
+3.8% YoY
|
| EBITDA |
-712.0K
est: 4.56M (-115.6%)
|
7.29M
est: 7.18M (+1.5%)
|
8.56M
est: 9.77M (-12.4%)
|
16.40M
est: 13.70M (+19.7%)
|
13.12M
est: 19.23M (-31.8%)
|
34.68M
est: 23.59M (+47.0%)
|
51.33M
est: 27.77M (+84.8%)
|
52.82M
est: 95.43M (-44.7%)
|
64.00M
est: 97.01M (-34.0%)
|
79.59M
est: 104.92M (-24.1%)
|
108.81M
106.51M – 111.30M
+3.7% YoY
|
112.46M
109.62M – 114.72M
+3.4% YoY
|
116.75M
115.41M – 118.10M
+3.8% YoY
|
| EBIT |
-819.5K
est: 2.56M (-132.0%)
|
6.81M
est: 4.04M (+68.6%)
|
7.41M
est: 9.34M (-20.6%)
|
14.41M
est: 11.92M (+20.9%)
|
9.57M
est: 17.26M (-44.5%)
|
15.30M
est: 21.18M (-27.8%)
|
29.08M
est: 24.93M (+16.6%)
|
31.78M
est: 52.32M (-39.3%)
|
32.72M
est: 53.19M (-38.5%)
|
41.73M
est: 57.53M (-27.5%)
|
59.67M
58.40M – 61.03M
+3.7% YoY
|
61.67M
60.11M – 62.90M
+3.4% YoY
|
64.02M
63.28M – 64.76M
+3.8% YoY
|
| Net Income |
-3.17M
est: 9.53M (-133.3%)
|
4.13M
est: 8.96M (-53.9%)
|
4.33M
est: 5.68M (-23.8%)
|
9.76M
est: 6.97M (+40.0%)
|
5.53M
est: 11.71M (-52.8%)
|
7.40M
est: 14.36M (-48.5%)
|
18.33M
est: 17.62M (+4.0%)
|
18.81M
est: 16.68M (+12.8%)
|
12.55M
est: 24.77M (-49.3%)
|
15.37M
est: 26.60M (-42.2%)
|
27.93M
27.30M – 30.97M
+5.0% YoY
|
34.46M
33.26M – 43.22M
+23.4% YoY
|
39.82M
38.51M – 51.55M
+15.6% YoY
|
| SGA |
444.0K
est: 893.2K (-50.3%)
|
1.73M
est: 1.41M (+23.0%)
|
1.84M
est: 8.39M (-78.1%)
|
3.12M
est: 15.75M (-80.2%)
|
4.02M
est: 14.64M (-72.6%)
|
5.23M
est: 17.97M (-70.9%)
|
6.04M
est: 21.14M (-71.4%)
|
8.21M
est: 16.75M (-51.0%)
|
17.35M
est: 17.03M (+1.8%)
|
50.20M
est: 18.42M (+172.5%)
|
19.10M
18.70M – 19.54M
+3.7% YoY
|
19.74M
19.24M – 20.14M
+3.4% YoY
|
20.50M
20.26M – 20.73M
+3.8% YoY
|
| EPS |
-0.73
est: 0.39 (-287.2%)
|
0.32
est: 0.37 (-12.7%)
|
0.31
est: 0.54 (-42.1%)
|
0.67
est: 0.78 (-14.1%)
|
0.36
est: 0.45 (-19.5%)
|
0.37
est: 0.83 (-55.4%)
|
0.77
est: 1.06 (-27.5%)
|
0.79
est: 0.67 (+18.5%)
|
0.51
est: 0.99 (-48.5%)
|
0.61
est: 1.05 (-41.8%)
|
1.18
1.09 – 1.24
+12.7% YoY
|
1.47
1.33 – 1.73
+24.3% YoY
|
1.69
1.54 – 2.06
+15.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi SDAX UCITS ETF Dist C005.DE | 0.50% | 894.4K | 0.70% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 23.0K | 0.30% |
| 3 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 157.2K | 0.42% |
| 4 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | 22.3K | 0.24% |
| 5 | Avantis International Equity ETF AVDE | 0.00% | 151.8K | 0.23% |
| 6 | Dimensional - International Small Cap ETF DFIS | 0.00% | 41.8K | 0.39% |
| 7 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 31.7K | 0.22% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 9.3K | 0.28% |
| 9 | Dimensional - International Vector Equity ETF DXIV | 0.00% | 41.85 | 0.53% |
| 10 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christoph Prusseit | Chief Business Officer of Germany & Member of Executive Board | 589.0K | male |
| Constantijn van Rietschoten | Chief Business Officer of International and Member of Executive Board | 589.0K | male |
| Falk Neukirch | Executive Officer | 579.0K | male |
| Claudia Nickolaus | Head of Investor, Public Relations, ESG & Communications | — | — |
| Stefan Bauerreis | CFO & Member of the Executive Board | — | male |
| Thomas Meier | CEO & Member of Executive Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ILM1.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
